Список литературы
1. Amman M.G., Singh N.N., Stewart A.W., Field C.J. Psychometric characteristics of the aberrant behavior checklist. Am. J. Ment. Def. 1985. Vol. 99. P. 492-502.
2. Baris S., Ercan H., Cagan H.H. Efficacy of intravenous immunoglobulin treatment in children. with common variable immunodeficiency. Immunol. 2011. Vol. 21(7). P. 514-521.
3. Billiau A.D., Witters P., Ceulemans B. et al. Intravevous immunoglobulins in refractory childhood-onset epilepsy: effects on seizure frequency, EEG activity and cerebrospinal fluid cytokine profile. Epilepsia. 2007. Vol. 48. P. 1739-1749.
4. Binstock T. Intra-monocyte pathogens delineate autism subgroups. Med. Hypotheses. 2001. – Vol. 56(4). P. 523-531.
5. Boris M., Goldblatt A., Edelson S.M., Edelson P.A.-C. Improvement in children with autism treated with intravenous gamma globulin. J. Nutr. Environ. Medicine. 2006. Vol. 15(4). P. 1-8.
6. Bradstreet J., Singh V.K., El-Dahr J. High dose intravenous immunoglobulin improves symptoms in children with autism. The international symposium on autism. 1999 Dec. 28. Atnhem, Netherlands.
7. Buchwald B., Ahangari R., Weishaupt A., Toyka K.V. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome. Annals of Neurology. 2002. Vol. 51. P. 673-680.
8. Cabanlit M., Wills S., Goines P. et al. Brain-specific autoantibodies in the plasma of subjects with autistic spectrum disorder. Ann. N. Y. Acad. Sci. 2007. Vol. 107. P. 92-103.
9. Chez G.M., Guido-Estrada N. Immune therapy in autism: historical experience and future directions with immunomodulatory therapy. Neurotherapeutists. 2010. Vol. 7. P. 293-301.
10. Ciric B., Van Keulen V., Paz Soldan M. et al. Antibody-mediated remyelination operates through mechanism independent of immunomodulation. J. Neuroimmunology. 2004. Vol. 146. P. 153-161.
11. Connery K., Tippett M., Delhey L.M., Rose S. Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism. Transl. Psychiatry. 2018. Vol. 8(1). P. 148.
12. Cowan J., Camero n D.W., Knoll G., Tay J. Protocol for updating a systematic review of randomised controlled trials on the prophylactic use of intravenous immunoglobulin for patients undergoing haematopoietic stem cell transplantation. BMJ Open. 2015. Vol. 5(8). e008316.
13. Croen L.A., Matevia M., Yoshida C.K., Grether J.K. Maternal Rh D status, anti-D immune globulin exposure during pregnancy, and risk of autism. Spectrumdisorders. Am. J. Obstet. Gynecol. 2008. Vol. 99(3). P. 234.
14. DelGiudice-Asch G., Simon L., Schmeidler J. Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism. J. Autism Dev. Disord. 1999. Vol. 29(2). P. 157-160.
15. Donati D., Akhyani N., Fogdell-Hahn A. et al. Detection of human herpesvirus-6 in mesial temporal lobe epilepsy surgical brain resections. Neurology. 2003. Vol. 61(10). P. 1405-1411.
16. Engman M.L., Sundin M., Miniscalco C. Prenatal acquired cytomegalovirus infection should be considered in children with autism. Acta Paediatr. 2015. Vol. 104(8). P. 792-795.
17. Finberg R.W., Newburger J.W., Mikati M.A. et al. Effect of high doses of intravenously administered immune globulin on natural killer cell activity in peripheral blood. J. Pediatr. 1992. Vol. 120(3). P. 376-380.
18. Frye R.E. Metabolic and mitochondrial disorders associated with epilepsy in children with autism spectrum disorder. Epilepsy Behav. 2015. Vol. 47. P. 147-157.
19. Ghaziuddin M., Al-Khouri I., Ghоaziuddin N. Autistic symptoms following herpes encephalitis. Eur. Child. Adolesc. Psychiatry. 2002. Vol. 11(3). P. 142-146.
20. Guo B.Q., Li H.B., Ding S.B. et al. Blood homocysteine levels in children with autism spectrum disorder: An updated systematic review and meta-analysis. Psychiatry Res. 2020. Vol. 291. P. 113283.
21. Gupta S. Treatment of children with autism with intravenous immunoglobulin. J. Child. Neurol. 1999. Vol. 14(3). P. 203-205.
22. Handen B.L., Melmed R.D., Hansen R.L. et al. A double-blind, placebo-controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder. J. Autism. Dev. Disord. 2009. Vol. 39(5). P. 796-805.
23. Heuer L., Ashwood P., Schauer J. et al. Reduced Levels of Immunoglobulin in Children With Autism Correlates With Behavioral Symptoms. Autism. Res. 2008. Vol. 1(5). P. 275-283.
24. Hiroshi H., Seiji K., Toshihiro K., Nobuo K. An adult case suspected of recurrent measles encephalitis with psychiatric symptoms. Seishin Shinkeigaku Zasshi. 2003. Vol. 105(10). P. 1239-1246.
25. Hughes H.K., Ko E.M., Rose D., Ashwood P. Immune Dysfunction and Autoimmunity as Pathological Mechanisms in Autism Spectrum Disorders. Front. Cell. Neurosci. 2018. Vol. 12. P. 405. doi: 10.3389/fncel.2018.00405.
26. Jyonouchi H., Geng L., Streck D.L., Toruner G.A. Immunological characterization and transcription profiling of peripheral blood (PB) monocytes in children with autism spectrum disorders (ASD) and specific polysaccharide antibody deficiency (SPAD): case study. J. Neuroinflammation. 2012. Vol. 9. P. 4.
27. Kamei A., Ichinohe S., Onuma R. et al. Acute disseminated demyelination due to primary human herpesvirus-6 infection. Eur. J. Pediatr. 1997. Vol. 156(9). P. 709-712.
28. Kooij S.J., Bejerot S., Blackwell A. et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry. 2010. Vol. 10. P. 67.
29. Li Y., Qiu S., Shi J. et al. Association between MTHFR C677T/A1298C and susceptibility to autism spectrum disorders: a meta-analysis. BMC Pediatr. 2020. Vol. 20(1). P. 449.
30. Maltsev D., Natrus L. The effectiveness of infliximab in autism spectrum disorders associated with folate cycle genetic deficiency. Psychiatry, Psychotherapy and Clinical Psychologythis. 2020. Vol. 11(3). P. 583-594.
31. Maltsev D.V. Efficacy of Rituximab in Autism Spectrum Di-sorders Associated with Genetic Folate Cycle Deficiency with Signs of Antineuronal Autoimmunity. Psychiatry, Psychotherapy and Clinical Psychologythis. 2021. Vol. 12(3). P. 471-486.
32. Maltsev D.V. Efficiency of a high dose of intravenous immunoglobulin in children with autistic spectrum disorders associated with genetic deficiency of folate cycle enzymes. Journal of global pharma technology. 2019. Vol. 11(05). P. 597-609.
33. Maltsev D.V. Features of folate cycle disorders in children with ASD. Bangladesh Journal of Medical Sciencethis. 2020. Vol. 19(4). P. 737-742.
34. Marchezan J., Winkler Dos Santos E.A., Deckmann I., Dos Santos Riesgo R. Immunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy. Neuroimmunomodulation. 2018. Vol. 25(5–6). P. 300-319. doi: 10.1159/000492225.
35. Marques F., Brito M.J., Conde M. Autism spectrum disorder secondary to enterovirus encephalitis. J. Child Neurol. 2014. Vol. 29(5). P. 708-714.
36. Masi A., Quintana D.S., Glozier N. et al. Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis. Mol. Psychiatry. 2015. Vol. 20(4). P. 440-446.
37. Melamed I.R., Heffron M., Testori A., Lipe K. A pilot study of high-dose intravenous immunoglobulin 5 % for autism: Impact on autism spectrum and markers of neuroinflammation. Autism Res. 2018. Vol. 11(3). P. 421-433.
38. Mohammad N.S., Shruti P.S., Bharathi V. et al. Clinical uti-lity of folate pathway genetic polymorphisms in the diagnosis of autism spectrum disorders. Psychiatr. Genet. 2016. Vol. 26(6). P. 281-286.
39. Monge-Galindo L., Pérez-Delgado R., López-Pisón J. Mesial temporal sclerosis in paediatrics: its clinical spectrum. Our experience gained over a 19-year period. Rev. Neurol. 2010. Vol. 50(6). P. 341-348.
40. Mostafa G.A., Al-Ayadhi L.Y. Increased serum levels of anti-ganglioside M1 auto-antibodies in autistic children: relation to the di-sease severity. J. Neuroinflammation. 2011. Vol. 25. P. 8-39.
41. Nicolson G.L., Gan R., Nicolson N.L., Haier J. Evidence for Mycoplasma ssp., Chlamydia pneunomiae, and human herpes virus-6 coinfections in the blood of patients with autistic spectrum disorders. J. Neurosci Res. 2007. Vol. 85(5). P. 1143-1148.
42. Niederhofer H., Staffen W., Mair A. Immunoglobulins as an alternative strategy of psychopharmacological treatment of children with autistic disorder. Neuropsychopharmacology. 2003. Vol. 28(5). P. 1014-1015.
43. Perlmutter S.J., Leitman S.F., Garvey M.A. et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet. 1999. Vol. 354(9185). P. 1153-1158.
44. Pinillos-Pisón R., Llorente-Cereza M.T., López-Pisón J. Congenital infection by cytomegalovirus. A review of our 18 years’ experience of diagnoses. Rev. Neurol. 2009. Vol. 48(7). P. 349-353.
45. Plebani A., Duse M., Tiberti S. Intravenous gamma-globulin therapy and serum IgG subclass levels in intractable childhood epilepsy. Monogr. Allergy. 1988. Vol. 23. P. 204-215.
46. Plioplys A.V. Intravenous immunoglobulin treatment of children with autism. J. Child. Neurol. 1998. Vol. 13(2). P. 79-82.
47. Price C.S., Thompson W.W., Goodson B. Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism. Pediatrics. 2010. Vol. 126(4). P. 656-664
48. Pu D., Shen Y., Wu J. Association between MTHFR gene polymorphisms and the risk of autism spectrum disorders: a meta-analysis. Autism Res. 2013. Vol. 6(5). P. 384-392.
49. Puangpetch A., Suwannarat P., Chamnanphol M. et al. Significant Association of HLA-B Alleles and Genotypes in Thai Children with Autism Spectrum Disorders: A Case-Control Study. Dis. Markers. 2015. Vol. 2015. P. 724935.
50. Rai V. Association of methylenetetrahydrofolate reductase (MTHFR) gene C677T polymorphism with autism: evidence of genetic susceptibility. Metab. Brain Dis. 2016. Vol. 31(4). P. 727-735.
51. Reinert P., Moulias R., Goust J.M. Demonstration of cellular immunity deficiency limited to measles virus in 20 cases of subacute sclerosing leukoencephalitis. Arch. Fr. Pediatr. 1972. Vol. 29(6). P. 655-665.
52. Rossignol D.A., Frye RE. A Systematic Review and Meta-Analysis of Immunoglobulin G Abnormalities and the Therapeutic Use of Intravenous Immunoglobulins (IVIG) in Autism Spectrum Disorder. J. Pers. Med. 2021. Vol. 11(6). P. 488.
53. Ruiz J.E., Kwak J.Y., Baum L. et al. Intravenous immunoglobulin inhibits natural killer cell activity in vivo in women with recurrent spontaneous abortion. Am. J. Reprod. Immunol. 1996. Vol. 35(4). P. 370-37.
54. Russo A.J., Krigsman A., Jepson B., Wakefield A. Low serum myeloperoxidase in autistic children with gastrointestinal disease. Clinical and Experimental Gastroenterology. 2009. Vol. 2. P. 85-94.
55. Sadeghiyeh T., Dastgheib S.A., Mirzaee-Khoramabadi K. et al. Association of MTHFR 677C>T and 1298A>C polymorphisms with susceptibility to autism: A systematic review and meta-analysis. Asian J. Psychiatr. 2019. Vol. 46. P. 54-61.
56. Saghazadeh A., Ataeinia B., Keynejad K. et al. A meta-ana-lysis of pro-inflammatory cytokines in autism spectrum disorders: Effects of age, gender, and latitude. J. Psychiatr. Res. 2019. Vol. 115. P. 90-102.
57. Santaella M.L., Varela Y., Linares N., Disdier O.M. Prevalence of autism spectrum disorders in relatives of patients with selective immunoglobulin A deficiency. P.R. Health. Sci J. 2008. Vol. 27(3). P. 204-208.
58. Schneider C.K., Melmed R.D., Barstow L.E. et al. Oral human immunoglobulin for children with autism and gastrointestinal dysfunction: a prospective, open-label study. J. Autism. Dev. Disord. 2006. Vol. 36(8). P. 1053-1064.
59. Singh V.K., Lin S.X., Newell E., Nelson C. Abnormal measles-mumps-rubella antibodies and CNS autoimmunity in children with autism. J. Biomed. Sci. 2002. Vol. 9(4). P. 359-364.
60. Singh V.K., Lin S.X., Yang V.C. Serological association of measles virus and human herpesvirus-6 with brain autoantibodies in autism. Clin. Immunol. Immunopathol. 1998. Vol. 89(1). P. 105-108.
61. Singh V.K., Warren R.P., Odell J.D. et al. Antibodies to myelin basic protein in children with autistic behavior. Brain. Behav. Immun. 1993. Vol. 7(1). P. 97-103.
62. Strunk T., Gottschalk S., Goepel W. Subacute leukencephalopathy after low-dose intrathecal methotrexate in an adolescent hete-rozygous for the MTHFR C677T polymorphism. Med. Pediatr. Oncol. 2003. Vol. 40(1). P. 48-50.
63. Torrente F., Ashwood P., Day R. et al. Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism. Mol. Psychiatry. 2002. Vol. 7(4). P. 375-382.
64. Warren R.P., Odell J.D., Warren W.L. et al. Brief report: immunoglobulin A deficiency in a subset of autistic subjects. J. Autism. Dev. Disord. 1997. Vol. 27(2). P. 187-192.
65. Wasilewska J., Kaczmarski M., Stasiak-Barmuta A. et al. Low serum IgA and increased expression of CD23 on B lymphocytes in peripheral blood in children with regressive autism aged 3–6 years old. Arch. Med. Sci. 2012. Vol. 8(2). P. 324-331.
66. Wynn J.L., Seed P.C., Cotten C.M. Does IVIg administration yield improved immune function in very premature neonates? J. Perinatol. 2010. Vol. 30(10). P. 635-642.
67. Yektaş Ç., Alpay M., Tufan A.E. et al. Comparison of serum B12, folate and homocysteine concentrations in children with autism spectrum disorder or attention deficit hyperactivity disorder and healthy controls. Neuropsychiatr. Dis. Treat. 2019. Vol. 15. P. 2213-2219.